IASLC IPASS Study 2

IASLC IPASS Study 2

In this special episode of Lung Cancer Considered, hosts Dr. Stephen Liu and Dr. Narjust Florez discuss the seminal IPASS trial with its principal investigator, Dr. Tony Mok. IPASS was a randomized phase III trial that compared the EGFR TKI gefitinib to carboplatin plus paclitaxel and showed, for the first time, that in a selected population, targeted therapy was superior to chemotherapy. The initial results were published in the New England Journal of Medicine in 2009 and helped usher in the era of precision oncology. Dr. Tony Mok is the Li Shu Fan Medical Foundation endowed Professor and Chairman of the Department of Clinical Oncology at the Chinese University of Hong Kong. He cofounded the Lung Cancer Research Group, Chinese Thoracic Oncology Research Group and Asia Thoracic Oncology Research Group.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(402)

Beyond Stage IV: Rethinking Oligometastatic Lung Cancer

Beyond Stage IV: Rethinking Oligometastatic Lung Cancer

In this episode, Dr. Narjust Florez is joined by Dr. Yasir Elamin and Dr. Liliana Faroni to explore the evolving management of oligometastatic lung cancer. They break down key definitions, discuss whe...

1 Syys 47min

LCC in Korean: The Role of Immunotherapy in Lung Cancer

LCC in Korean: The Role of Immunotherapy in Lung Cancer

In this Korean-language episode of Lung Cancer Considered, Dr. Chul Kim is joined by Dr. Hye-Ryun Kim and Dr. Young Kwang Chae to discuss the evolving role of immunotherapy across the lung cancer trea...

28 Elo 46min

The Global Fight Against Lung Cancer: A Conversation with WHO's José Luis Castro

The Global Fight Against Lung Cancer: A Conversation with WHO's José Luis Castro

Host Dr. Stephen Liu is joined by José Luis Castro, WHO Director-General Special Envoy for Chronic Respiratory Diseases, for a thought-provoking discussion on why lung cancer must be recognized as a g...

25 Elo 29min

LCC: Grace Under Pressure: Navigating Burnout and Loss in Oncology

LCC: Grace Under Pressure: Navigating Burnout and Loss in Oncology

In this episode of Lung Cancer Considered, host Dr. Narjust Florez is joined by Dr. Mark Lewis and Dr. Michael Maddaus for a candid conversation about physician wellness, burnout, grief, and resilienc...

18 Elo 47min

LCC Advances in ALK+ Cancer in Cantonese

LCC Advances in ALK+ Cancer in Cantonese

As part of IASLC’s ongoing series of Lung Cancer Considered podcasts in world languages, Dr. Molly Li moderates a discussion in Cantonese with Dr. Tony Mok, Dr. Chao Zhang, and Dr. Wen-Zhao Zhong. The...

14 Elo 46min

Treating Advanced Thymic Cancers

Treating Advanced Thymic Cancers

Thymic epithelial tumors are rare but complex thoracic cancers that require specialized diagnosis and multidisciplinary management. In this episode of Lung Cancer Considered, Dr. Stephen Liu is joined...

4 Elo 59min

FDA Approval: Zidesamtinib and ROS1 NSCLC

FDA Approval: Zidesamtinib and ROS1 NSCLC

Patients with ROS1-positive NSCLC have a new treatment option following the FDA approval of zidesamtinib for those previously treated with a ROS1 tyrosine kinase inhibitor. In this episode, Dr. Stephe...

28 Heinä 24min

Rewriting the Playbook: Cellular Therapy and Vaccines for ALK-Positive Lung Cancer

Rewriting the Playbook: Cellular Therapy and Vaccines for ALK-Positive Lung Cancer

How could cellular therapies and cancer vaccines transform the future of treatment for ALK-positive lung cancer? Host Dr. Narjust Florez sits down with Dr. Vincent Lam and Dr. Carmen Mecca to explore ...

21 Heinä 47min

Suosittua kategoriassa Tiede

rss-poliisin-mieli
tiedekulma-podcast
utelias-mieli
rss-luontopodi-samuel-glassar-tutkii-luonnon-ihmeita
filocast-filosofian-perusteet
rss-mita-tulisi-tietaa
hippokrateen-vastaanotolla
docemilia
rss-duokkari-ekstra
rss-tiedetta-vai-tarinaa
rss-totuuden-liepeilla
rss-ja-ihminen-loi-alyn-aalto-yliopiston-tekoalypodcast
rss-duodecim-lehti
rss-murremyytin-murtajat
rss-hereilla
sotataidon-ytimessa
rss-kova-luonto